Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

evenue for 2008 is expected to be approximately $10 million to $12 million, resulting from Keflex product sales and assuming no generic competition to Keflex 750 mg capsules occurs during the year. Total cash used in operating activities and capital expenditures in 2008 is estimated to be between $17 and $19 million. These forecasts also assume no financial impact from the Company's recently approved MOXATAG product, pending the outcome of its ongoing strategic process.

Assuming the Company's expectations for continued sales of its Keflex 750 mg product and anticipated level of R&D spending and other obligations, MiddleBrook believes that its current funds, together with expected Keflex product sales, will be sufficient to support its currently planned operations into 2009. These 2008 estimates are forward-looking statements that involve risks and uncertainties, and actual results could vary materially.

CONFERENCE CALL

The Company has scheduled a conference call for today, Tuesday, March 4, 2008 at 10:30 AM ET. During the call, Dr. Edward Rudnic, president and CEO, and Robert Low, vice president, finance and CFO, will discuss quarterly results and other corporate activities. Investors can call 1-800-813-8504 (domestic) and 1-706-643-7752 (international) prior to the 10:30 AM start time and ask for the MiddleBrook Pharmaceuticals conference call hosted by Dr. Rudnic. A replay of the call will be available on Tuesday, March 4, 2008 beginning at 12:30 PM ET and will be accessible until Tuesday, March 11, 2008 at 5:00 PM ET. The replay call-in number is 1-800-642-1687 for domestic callers and 1-706-645-9291 for international callers. The access number is 37507035.

The conference call will also be broadcast simultaneously on the Company's website, http://www.middlebrookpharma.com. Investors should click on the Investor Relations tab and are advised to go to the website at least 15 mi
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 30, 2015  The University of California, San ... and UC San Diego Extension announced their third ... Aug.  12 – 14, 2015, at UC San ... provides an intense exposure to best practices and ... well-suited to biologists, process engineers and business executives ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... first participant in its Phase 1/2 clinical trial ... chronic unilateral Achilles tendinosis, has been enrolled and ... intra-tendon ultrasound-guided injections. RCT-01 is comprised of non-bulbar ...
(Date:6/30/2015)... ... June 30, 2015 , ... Southern ... accepted the position of vice president of instruction at Chippewa Valley Technical College ... greatly appreciated the opportunity to lead SIUE during the past three years,” Furst-Bowe ...
(Date:6/30/2015)... Florida (PRWEB) , ... June 30, 2015 , ... ... cannabis digital media company, launched “Cannavoices,” an unprecedented digital video and broadcast ... largest but also the most dynamic collection of legal medical cannabis stories ever ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... the "Company" TSX: DDD; OTCBB: DRUG; BBSE: DRP), a leading,international pharmaceutical ... 31, 2007., 2007 Full Year Financial Highlights:, - ... in 2006 - Chemical Division,s ... $45.8 million in 2006. ...
... 31 NxStage Medical,Inc. (Nasdaq: NXTM ), ... that Tom Shea has joined the Company as ... 2008. Mr.,Shea will be responsible for all of ... Mr. Shea joins NxStage with more than ...
... MANASQUAN, NJ., March 31 BioSpace, the world,s leading,online ... will host,the Biotech Beach(TM) Career in La Jolla, CA ... at the Hyatt Regency La Jolla from 2 pm-7 ... science professionals from across Southern California will attend,the biotech ...
Cached Biology Technology:Dragon Pharma announces 2007 full year financial results 2Dragon Pharma announces 2007 full year financial results 3Dragon Pharma announces 2007 full year financial results 4Dragon Pharma announces 2007 full year financial results 5Dragon Pharma announces 2007 full year financial results 6Dragon Pharma announces 2007 full year financial results 7NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations 2NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations 3Bioscience Career Fair in San Diego Expected to Draw Record Jobseeker Attendance 2
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
(Date:6/23/2015)...   Valencell, a leader in performance ... recent study that illustrates its PerformTek biometric technology ... In a study conducted at Valencell,s Biometric Lab, ... Apple Watch against a chest strap – the ... The study demonstrated that Valencell,s biometric technology delivers ...
(Date:6/17/2015)... Germany , June 17, 2015 ... QIA) today launched new Investigator ® STR assay kits ... the United States . The new genetic fingerprint ... genomic markers (short tandem repeats or STRs) for DNA matching. ... the quality of DNA in each sample, a novel QIAGEN ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... (June 28 2013) A study carried out in India ... bone marrow stem cells in patients with type 2 ... when compared to a control group of TD2M patients ... , The study appears as an early e-publication for ...
... make a big difference. A "left-handed" molecule of a ... its mirror-image "right-handed" counterpart could be completely inactive. That,s ... crucial: Living organisms are made only from left-handed amino ... Now, a team of scientists at the U.S. ...
... the late spring, the 4000 elk of the Clarks ... following the greening grass into the highlands of the ... on vegetation fed by snowmelt. It,s a short trip ... uncommonly free of roads, fences, metropolitan areas, and other ...
Cached Biology News:Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use 2Tiny nanocubes help scientists tell left from right 2Tiny nanocubes help scientists tell left from right 3Declining fortunes of Yellowstone's migratory elk 2Declining fortunes of Yellowstone's migratory elk 3Declining fortunes of Yellowstone's migratory elk 4
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Rabbit polyclonal antibody to GluR2...
... Blocker Array II can be used to ... various proteins and sera that are commonly ... The array contains spots for 19 different ... Determination of antibody crossreactivity and species specificity, ...
... sufficient materials for 1,464 array sample elements. , ... , Blocker BSA in PBS (10X): 50 ... 10 g , BupH Phosphate Buffered ... 2 x 10 ml ampules , SuperSignal West ...
Biology Products: